Move above 17,300 could take Nifty towards 17,800: Analysts

Move above 17,300 could take Nifty towards 17,800: Analysts

Technical analysts expect the Nifty to test 17,300 in the short term after the index closed above the 17,000-mark for the first time in nearly two months on Friday. The Nifty ended with a gain of 2.6% last week at 17,158.25. If it crosses 17,300, a further upmove towards 17,800 cannot be ruled out, said … Read more

Stocks to buy today: 10 short-term trading ideas by experts for 29 July

Stocks to buy today: 10 short-term trading ideas by experts for 29 July

Indian market started on a strong note on Friday tracking positive global cues. The S&P BSE Sensex rallied over 500 points while the Nifty50 reclaimed 17,000 levels in the first 15-minutes of trade. Sectorally, the rally was seen in metals, realty, auto, capital goods, and power stocks while some selling was visible in the healthcare … Read more

Rupee at 80/USD! How to tweak your equity portfolio to gain from stronger dollar

Rupee at 80/USD! How to tweak your equity portfolio to gain from stronger dollar

NEW DELHI: With the Indian rupee crossing the 80 level against the US dollar, experts say the changing dynamics in the forex market can be a tailwind for stock investors in a turbulent market if their portfolios are positioned accordingly. While the strategy is simple – increase weightage on exporters and trim holdings in importers … Read more

Stocks to buy today: 8 short-term trading ideas from experts

Stocks to buy today: 8 short-term trading ideas from experts

Indian market started on a strong note on Friday, tracking positive global cues. The S&P BSE Sensex rallied nearly 300 points while Nifty50 reclaimed 16,000 levels in the first 15 minutes of trade. The rupee hit a fresh record low for the 5th day as it touched 79.94 against the US dollar. Sectorally, buying was … Read more

Can PLI, China Plus One keep India’s pharma sector in pink of health?

Can PLI, China Plus One keep India’s pharma sector in pink of health?

The US economy also witnessed substantial issues in its pharma market. In addition to these, manufacturing & exporting countries around the world saw heightened raw material price inflation followed by supply chain disruption. All these affected the margins of the companies deeply. Synopsis Indian pharmaceutical market flattened after the pandemic led to a massive upsurge … Read more

2 stocks ideas by Kunal Bothra for coming week

2 stocks ideas by Kunal Bothra for coming week

“I am extremely positive on the market at least for the very near term. The base has definitely shifted up higher from 15700 to 16000 on the Nifty,” said Kunal Bothra, kunalbothra.co.in. Edited excerpts: Bank Nifty came back strongly and short covering was in place for many individual stocks. The biggest positive sign was that … Read more

Nifty 50 cos may post 21% growth in June quarter earnings on low base

Nifty 50 cos may post 21% growth in June quarter earnings on low base

Mumbai: Nifty 50 companies are likely to report year-on-year (YoY) growth of 32% and 21% in revenues and profits, respectively, in the June 2022 quarter (Q1) on the back of a low base, according to analysts‘ estimates. Excluding financial, telecom and commodities, the revenue and profit growth will likely come in at 22% and 16%, … Read more

Wondering what this earnings season has in store? Check out brokers’ sector-wise preview

Wondering what this earnings season has in store? Check out brokers’ sector-wise preview

A host of brokerages have come out with reports, offering insights into how various sectors performed in the June quarter and what investors should expect going into the results season. While a few sectors are yet to be previewed by analysts, those previewed are discussed below: IT sector Kotak Institutional Equities expect divergent performance across … Read more

US speciality biz, India rebound help Sun Pharma shine in Q2

US speciality biz, India rebound help Sun Pharma shine in Q2

The management intends to ramp up the speciality business to a reasonable scale before allocating investments in new areas. Synopsis India business, contributing a third of the company’s consolidated revenues, grew on the back of a recovery in non-Covid drug therapies leading to gains for the industry leader. The market is gradually moving back to … Read more